Franz-Werner Haas, CureVac CEO (AP Images)
July 5, 2022 09:08 AM EDTUpdated 01:38 PM
Pharma
Law

Left be­hind at the Covid vac­cine start­ing line, Cure­Vac files suit against BioN­Tech over megablock­buster IP claims

John Carroll

Editor & Founder

BioN­Tech and their Big Phar­ma part­ners at Pfiz­er hand­i­ly beat Ger­many’s Cure­Vac to the mar­ket with a megablock­buster mR­NA vac­cine to fight Covid-19. But Cure­Vac …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times